-+ 0.00%
-+ 0.00%
-+ 0.00%

Fate Therapeutics launches Phase 1/2 COMPLETE trial of FT839 dual-CAR T therapy in rheumatoid arthritis

PUBT·09/16/2026 11:01:40
Listen to the news
Fate Therapeutics launches Phase 1/2 COMPLETE trial of FT839 dual-CAR T therapy in rheumatoid arthritis
  • Fate Therapeutics secured four ACR Convergence 2026 poster slots for its off-the-shelf CAR T-cell autoimmune programs.
  • Updated FT819 clinical results will be presented in November, including dosing without conditioning chemotherapy and progress toward outpatient, same-day discharge use.
  • Data also link treatment response to improvements in patient-reported quality of life, supporting a broader community-care rollout strategy.
  • FT839 preclinical update will outline the COMPLETE Phase 1/2 trial design and early progress in rheumatoid arthritis ahead of the meeting.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fate Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609160700PRIMZONEFULLFEED9827862) on September 16, 2026, and is solely responsible for the information contained therein.